Tango Therapeutics, Inc. (TNGX) financial statements and ratios from SEC XBRL: revenue $0.1B (TTM), net margin -162.9%, revenue growth -100.0% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $62.38M |
| Revenue (TTM) | $0.1B |
| Net Margin | -162.9% |
| Return on Equity | -12.1% |
| Operating Margin (TTM) | -165.9% |
| Current Ratio | 50.82 |
| Revenue Growth (YoY) | -100.0% |
| EPS Growth (YoY) | 5.7% |
| FCF Growth (YoY) | 124.0% |
| Price / Book | 3.35 |
| Price / Sales | 63.84 |
| FCF Yield | -4.1% |
| Altman Z-Score | 36.84 (safe) |
| Industry P/E (Pharmaceutical Products) | 15.1 |
| Sector P/E (Healthcare) | 19.4 |
TNGX overview · TNGX earnings · TNGX KPIs · TNGX documents · TNGX ownership · TNGX peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.